Esperion Therapeutics, Inc. 4

President and CEO Sheldon L. Koenig disposed of 2,121,094 Esperion common shares and 2,042,460 in‑the‑money option-linked shares for cash at $3.16 per share (plus CVRs) in a merger, exiting his equity position.

On July 13, 2026, President and CEO Sheldon L. Koenig disposed of all his equity interests in Esperion Therapeutics, Inc. in connection with the closing of a merger in which Esperion became a wholly owned subsidiary of Essence Parent Inc. All 2,121,094 shares of common stock (including 1,474,344 RSUs and 1,983 ESPP shares) were converted into the right to receive $3.16 per share in cash plus one contingent value right (CVR) per share, and all in‑the‑money stock options were canceled in exchange for cash equal to the intrinsic value (the $3.16 merger price less the option exercise price) plus one CVR per underlying share. Specifically, options for 642,000 shares at a $2.05 strike, 753,000 shares at a $1.50 strike, and 647,460 shares at a $2.44 strike were terminated for cash and CVRs, leaving Koenig with no remaining common stock or option ownership in Esperion post‑merger. Based on the merger consideration, the common stock position represented roughly $6.7 million in cash value plus CVRs, while the in‑the‑money options represented roughly $1.9 million in intrinsic value plus CVRs, for an estimated aggregate transaction value of approximately $8.6 million excluding any future CVR payouts.

Filing Facts

CIK

1434868

Ticker

ESPR

Form

4

Source Type

fda

Accession

0001628280-26-047999

Alert Tier

7